Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Pamplona – page 40

753 clinical trials in Pamplona, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Pamplona at a glance
753
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

753 trials in Pamplona

Open in trial search

Breast cancer+7

Not recruiting

Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Graft versus host disease+1

Not recruiting

Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Itolizumab
  • Sponsor:Equillium Inc.

Colorectal cancer metastatic

Not recruiting

Study of Nous-209 Genetic Vaccine and Pembrolizumab for Patients with Advanced Microsatellite Instability-High Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gad20-209-Fsp-A1
  • Sponsor:Nouscom S.r.l.

Urticaria chronic+2

Not recruiting

Study on Remibrutinib for Adults with Chronic Inducible Urticaria Uncontrolled by H1-Antihistamines

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Squamous cell carcinoma of head and neck

Not recruiting

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Squamous cell carcinoma of head and neck

Not recruiting

Study of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Genmab A/S

Squamous cell carcinoma of head and neck

Not recruiting

Study of Niraparib and Dostarlimab with Radiotherapy for Patients with Locally-Advanced Head and Neck Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Grupo Espanol De Tratamiento De Tumores De Cabeza Y Cuello

Cardiac amyloidosis

Not recruiting

Study on the Safety of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy Who Completed a Previous Trial

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis Hydrochloride
  • Sponsor:Eidos Therapeutics Inc.

Partial seizures

Not recruiting

Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bhv-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Plasma cell myeloma

Not recruiting

Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Neoplasm

Not recruiting

Study of EGL-001 for Adults with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Egl-001
  • Sponsor:Egle Therapeutics

Neoplasm

Not recruiting

Study of RLY-4008 for Patients with Cholangiocarcinoma and Other Advanced Solid Tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Rly-4008
  • Sponsor:Elevar Therapeutics Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Pamplona

What the registry says about research in the country

01 Oncology Research

Innovative trials exploring treatments for various cancers, including metastatic colorectal cancer, bladder cancer, and prostate cancer. Studies focus on combination therapies and novel treatment approaches.

  • Colorectal Cancer Treatment Studies
  • Prostate Cancer Therapies
  • Blood Cancer Research

Multiple trials evaluating immunotherapies and targeted treatments for improving patient outcomes.

02 Immunology and Inflammation

Research focused on treating autoimmune conditions and inflammatory disorders, including studies on cutaneous lupus erythematosus and atopic dermatitis.

  • Lupus Treatment Studies
  • Dermatological Conditions
  • Immune System Disorders

Evaluating new therapeutic approaches for chronic inflammatory conditions.

03 Respiratory Medicine

Clinical investigations targeting respiratory conditions, including studies on COPD and respiratory viral infections. Research focuses on improving treatment outcomes.

  • COPD Management
  • Respiratory Virus Prevention
  • Nasal Polyps Treatment

Development of innovative therapies for respiratory diseases and infections.

04 Metabolic Disorders

Studies addressing obesity, diabetes, and related metabolic conditions. Research focuses on weight management and blood sugar control.

  • Type 2 Diabetes Treatment
  • Weight Management Therapies
  • Metabolic Disease Research

Investigating new approaches for metabolic disorder management.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.